TRU-SENTIMENT · DeltaNeutral
TNGX Trading Analysis - 11/20/2026 10:14 AM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
TNGX (Tango Therapeutics Inc.) at $22.57. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $0 vs put $119,380. RSI 51.1.
- Symbol
- TNGX
- Price
- $22.57
- Article bias (separate from True Sentiment)
- bearish
- Conviction
- medium
- Published
- 2026-11-20 10:14:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow via True Sentiment (Delta 40-60 only) shows Bearish conviction:
Call Volume: $0 (0.0%) Put Volume: $119,380 (100.0%) Total: $119,380
137 put contracts across 5 trades vs 0 call contracts implies one-sided directional put buying. Sentiment is Bearish with filter ratio 1.1% (5 of 472 total options analyzed). This pure directional positioning suggests near-term downside expectations, diverging from the neutral RSI (51.06) and a slightly positive 11-19 daily close (+3.5% from 11-18). The bearish flow contrasts with price stabilizing above $22.00, a notable sentiment/price divergence.
Key Statistics: TNGX
Fundamental Snapshot
Valuation
| EPS (trailing 12 mo) | $-1.37 |
| Market cap | $3.81B |
| Shares outstanding | 169.5M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.99 |
| 52-week low | $7.83 |
| 52-week high | $34.39 |
| Historical volatility | 95.8% |
Ownership & trading
| Institutional ownership | 47.2% |
| Average daily volume | 4.0M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
The following items are based on general knowledge and are provided for contextual framing only, separate from the data-driven analysis below.
- TNGX (Tempus Therapeutics / molecular oncology focus) has been volatile amid broader biotech sector repositioning following mixed clinical trial readouts in late 2026.
- Recent headlines suggest a delay in a key pipeline catalyst, reducing near-term speculative momentum versus the October highs near $27.65.
- Institutional ownership sits near 47.2%, implying moderate but not dominant sponsor flow, consistent with post-runup distribution seen in the daily history.
- No confirmed earnings date imminent from provided data; fiscal year end listed as 2025-12-01, suggesting annual reporting cycle not a near-term intraday catalyst.
- Context: The bearish options flow and sub-SMA price action align with a "news void + technical decay" environment rather than a fresh positive catalyst.
Fundamental Analysis
Based strictly on the embedded FUNDAMENTALS data:
- Trailing EPS is -1.37; the company is not profitable (negative earnings). Trailing PE, forward PE, and PEG are all null — standard valuation ratios are not computable from provided data.
- Revenue growth, gross/operating/net margins, ROE, and free cash flow are null — no profitability or growth trend can be derived from the data.
- Debt/equity is null; however, negative EPS and null cash flow metrics suggest a pre-profit clinical-stage profile.
- Market cap is $3.81B with 169.46M shares outstanding; 52-week range is $7.83 to $34.39, indicating the current $22.79 is mid-range but well off highs.
- Institutional ownership is 47.21%; beta is 0.99 (market-neutral relative volatility).
- Analyst consensus and target mean price are null — no street anchor is provided.
- Fundamentals (no earnings, no yield) diverge from the technical picture: price is holding above the 52-week mid but below all major SMAs, reflecting a speculatively valued name with no fundamental support in the dataset.
Current Market Position
Current price per indicators is $22.79 (as of 2026-11-19 close). Minute bars show 2026-11-20 open at $22.11, low $21.95, and 09:45 close at $22.57 after an early dip. Recent daily action: 11-17 close $22.32, 11-18 close $22.02, 11-19 close $22.79 (intraday high $23.66). Price remains below SMA-5 ($23.34), SMA-20 ($23.11), and SMA-50 ($23.51).
Intraday momentum on 11-20 is tentative: after a gap-down open to $22.11, price recovered to $22.57 by 09:45 on 15,788 volume, but still below prior session VWAP context.
Technical Analysis
Technical Indicators
SMA alignment is bearish: price ($22.79) < SMA-5 ($23.34) < SMA-20 ($23.11) < SMA-50 ($23.51) — all stacked negatively, no bullish crossover. RSI at 51.06 is neutral, lacking directional momentum. MACD (-0.05) below signal (-0.04) with negative histogram (-0.01) shows mild bearish pressure. Bollinger mid is $23.11; price is below mid and closer to lower band ($20.63) than upper ($25.60) — no squeeze, normal expansion. 30-day range high $27.65, low $20.74; current $22.79 is ~26% above the 30-day low and ~17% below the high, confirming a lower-half range position.
True Sentiment Analysis (Delta 40-60 Options)
Options flow via True Sentiment (Delta 40-60 only) shows Bearish conviction:
Call Volume: $0 (0.0%) Put Volume: $119,380 (100.0%) Total: $119,380
137 put contracts across 5 trades vs 0 call contracts implies one-sided directional put buying. Sentiment is Bearish with filter ratio 1.1% (5 of 472 total options analyzed). This pure directional positioning suggests near-term downside expectations, diverging from the neutral RSI (51.06) and a slightly positive 11-19 daily close (+3.5% from 11-18). The bearish flow contrasts with price stabilizing above $22.00, a notable sentiment/price divergence.
Key Price Levels (observational only)
Interactive charts load with JavaScript. This text is the crawlable summary.